EW
BIB icon

Evoke Wealth’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Evoke Wealth’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-700
Closed -$29.8K – 1270
2019
Q3 		$29.8K Buy
+700
New +$33.2K ﹤0.01% 566

Other funds holding BIB

GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
SW
SkyOak Wealth Southfield, Michigan $546M AUM 18.14% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

Evoke Wealth's BIB Position: Q4 2019 in Review

Evoke Wealth sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2019, closing a stake of 700 shares — an estimated $29.8K sold.

Evoke Wealth first reported a position in BIB in Q3 2019 and held it in 1 quarter. The position peaked at $29.8K in Q3 2019. 26 funds tracked by Wall St. Rank hold BIB as of Q4 2019.

  • Evoke Wealth reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Evoke Wealth sold 700 ProShares Ultra NASDAQ Biotechnology shares in Q4 2019, an estimated $29.8K.
  • Evoke Wealth first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2019 and held it in 1 quarter.
  • Evoke Wealth's ProShares Ultra NASDAQ Biotechnology position peaked at $29.8K in Q3 2019.
  • 26 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2019.

Based on Evoke Wealth's 13F filing for Q4 2019, filed 7 Feb 2020.